Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon α2b in patients with metastatic melanoma

Oncology Reports

Volumn 20, Issue 6, 2008, Pages 1533-1538

  Bar, Jair ^a,d   Yerushalmi, Rinat ^b,d   Shapira Frummer, Roni ^a   Kutchuk, Irena ^a   Sulkes, Aaron ^b,d   Gutman, Haim ^c,d   Catane, Raphael ^a,d   Schachter, Jacob ^a,d  

^a SHEBA MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c RMC   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemobiotherapy; Complete response; Metastatic melanoma

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 2; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOPSY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLOSTRIDIUM DIFFICILE INFECTION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; DRY SKIN; ELECTROLYTE DISTURBANCE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEMODIALYSIS; HUMAN; HYPOTENSION; HYPOXEMIA; INFECTION; ISRAEL; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN EXFOLIATION; SKIN TOXICITY; SUBSTITUTION THERAPY; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; WEIGHT GAIN; MIDDLE AGED; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 59249086430     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000176     Document Type: Article

References (25)

1. Tsao H, Atkins MB and Sober AJ: Management of cutaneous melanoma. N Engl J Med 351: 998-1012, 2004.
2. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907-913, 1994.
3. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105-2116, 1999.
4. O'Day SJ, Gammon G, Boasberg PD, et al: Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 17: 2752-2761, 1999.
5. Casares N, Pequignot MO, Tesniere A, et al: Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202: 1691-1701, 2005.
6. Lake RA and Robinson BW: Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5: 397-405, 2005.
7. Lake RA and van der Most RG: A better way for a cancer cell to die. N Engl J Med 354: 2503-2504, 2006.
8. Legha SS, Ring S, Eton O, et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752-1759, 1998.
9. Eton O, Legha SS, Bedikian AY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 20: 2045-2052, 2002.
10. Keilholz U, Goey SH, Punt CJ, et al: Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15: 2579-2588, 1997.
11. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17: 968-975, 1999.
12. Ridolfi R, Chiarion-Sileni V, Guida M, et al: Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20: 1600-1607, 2002.
13. Bajetta E, Del Vecchio M, Nova P, et al: Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 17: 571-577, 2006.
14. Ives NJ, Stowe RL, Lorigan P and Wheatley K: Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 25: 5426-5434, 2007.
15. Flaherty LE, Atkins M, Sosman J, et al: Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol 19: 3194-3202, 2001.
16. Keilholz U, Scheibenbogen C, Tilgen W, et al: Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 72: 607-614, 1993.
17. O'Day SJ, Boasberg PD, Piro L, et al: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 8: 2775-2781, 2002.
18. Chang DZ, Lomazow W, Joy Somberg C, Stan R and Perales MA: Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 9: 207-215, 2004.
19. Keilholz U and Gore ME: Biochemotherapy for advanced melanoma. Semin Oncol 29: 456-461, 2002.
20. Weber RW, O'Day S, Rose M, et al: Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 23: 8992-9000, 2005.
21. Ron IG, Sarid D, Ryvo L, et al: A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. Melanoma Res 16: 65-69, 2006.
22. Legha SS, Ring S, Eton O, Bedikian A, Plager C and Papadopoulos N: Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 3 (Suppl 1): S9-S15, 1997.
23. Thompson JA, Gold PJ and Fefer A: Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Semin Oncol 24: S44-S48, 1997.
24. Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG and Fefer A: Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 3 (Suppl 1): S29-S34, 1997.
25. Schachter J, Rakowsky E, Sulkes A and Adler A: A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF-an innovative protocol for the treatment of metastatic melanoma. Cancer Biother Radiopharm 13: 155-164, 1998.